Nan Fung Group Holdings Ltd lowered its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 80.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,095 shares of the company's stock after selling 148,380 shares during the quarter. Nan Fung Group Holdings Ltd owned 0.18% of DBV Technologies worth $115,000 at the end of the most recent quarter.
DBV Technologies Stock Performance
DBVT traded down $0.28 on Thursday, reaching $8.98. The company had a trading volume of 133,027 shares, compared to its average volume of 182,095. The company's fifty day moving average is $5.73 and its 200 day moving average is $4.40. The stock has a market cap of $184.76 million, a P/E ratio of -2.00 and a beta of -0.08. DBV Technologies S.A. has a fifty-two week low of $2.20 and a fifty-two week high of $9.59.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The firm had revenue of $0.51 million for the quarter. On average, sell-side analysts expect that DBV Technologies S.A. will post -7.05 EPS for the current year.
Analyst Ratings Changes
Several research firms recently issued reports on DBVT. JMP Securities reiterated a "market outperform" rating and set a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th. StockNews.com started coverage on DBV Technologies in a research note on Wednesday. They set a "hold" rating for the company.
Get Our Latest Report on DBV Technologies
DBV Technologies Company Profile
(
Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Stories
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
